- Report
- July 2024
- 155 Pages
Global
From €3288EUR$3,613USD£2,793GBP
€3868EUR$4,250USD£3,285GBP
- Report
- July 2024
- 153 Pages
Global
From €3288EUR$3,613USD£2,793GBP
€3868EUR$4,250USD£3,285GBP
- Report
- December 2024
Global
From €6826EUR$7,500USD£5,798GBP
- Report
- April 2025
- 210 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- March 2025
- 197 Pages
Global
From €4505EUR$4,950USD£3,827GBP
- Report
- March 2025
- 110 Pages
Global
From €2685EUR$2,950USD£2,281GBP
- Report
- December 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- October 2024
- 200 Pages
United States
From €2266EUR$2,490USD£1,925GBP
- Report
- October 2024
- 200 Pages
Europe
From €2266EUR$2,490USD£1,925GBP
- Report
- March 2025
- 120 Pages
North America
From €3641EUR$4,000USD£3,092GBP
- Report
- August 2024
- 80 Pages
United States
From €3186EUR$3,500USD£2,706GBP
- Report
- July 2024
- 97 Pages
Africa, Middle East
From €3140EUR$3,450USD£2,667GBP
- Report
- January 2025
- 97 Pages
Africa, Middle East
From €3140EUR$3,450USD£2,667GBP
- Report
- January 2025
- 104 Pages
North America
From €3140EUR$3,450USD£2,667GBP
- Report
- October 2024
- 114 Pages
North America
From €3140EUR$3,450USD£2,667GBP
- Report
- October 2024
- 109 Pages
Middle East, Africa
From €3140EUR$3,450USD£2,667GBP
- Report
- October 2024
- 126 Pages
Europe
From €3140EUR$3,450USD£2,667GBP
- Report
- March 2025
- 82 Pages
Middle East, Africa
From €2685EUR$2,950USD£2,281GBP
- Report
- March 2025
- 96 Pages
Asia Pacific
From €3140EUR$3,450USD£2,667GBP
- Report
- March 2025
- 99 Pages
Europe
From €3140EUR$3,450USD£2,667GBP

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated.
Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss.
In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR.
The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR.
Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more